Vaxart Inc (VXRT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vaxart Inc (VXRT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8006
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vaxart Inc (Vaxart) is a clinical stage biotechnology company which develops oral recombinant protein vaccines based on its proprietary oral vaccine delivery platform to treat infections. The company develops tablet vaccines for seasonal and pandemic influenza, norovirus, and respiratory syncytial virus (RSV). Vaxart’s vaccine delivery platform encompasses vector-adjuvant combination, which can be used with many recombinant antigens to develop vaccines for oral administration. The company’s platform approach supports the rapid development of antigen based vaccines. It offers recombinant protein antigens such as marketed influenza, hepatitis B, human papilloma virus (HPV) vaccines, and other recombinant vaccines in industry pipeline. The company also conducts studies for the development of vaccine candidates for other indications. Vaxart is headquartered in South San Francisco, California, the US.

Vaxart Inc (VXRT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Vaxart Raises US$20 Million In Series C Financing Round 11
Vaxart Raises Additional US$4.4 Million In Series B Financing 12
Partnerships 13
Vaxart Enters into Contract with BARDA 13
Merger 14
Aviragen Therapeutics Completes Merger With Vaxart 14
Debt Offering 15
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc – Key Competitors 16
Vaxart Inc – Key Employees 17
Vaxart Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Vaxart announces second quarter 2018 financial results and corporate update 19
May 15, 2018: Vaxart Announces First Quarter 2018 Financial Results and Corporate Update 20
Corporate Communications 21
May 01, 2018: Vaxart Names Dr. David Taylor As Chief Medical Officer 21
Apr 19, 2018: Vaxart Appoints Brant Biehn As Senior Vice President, Commercial Operations 22
Clinical Trials 23
Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma 23
Apr 02, 2018: Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress 24
Jan 31, 2018: Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study 25
Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 26
Oct 26, 2017: Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study 27
Feb 14, 2017: Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine 28
Feb 13, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir 29
Feb 01, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Vaxart Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9
Vaxart Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxart Raises US$20 Million In Series C Financing Round 11
Vaxart Raises Additional US$4.4 Million In Series B Financing 12
Vaxart Enters into Contract with BARDA 13
Aviragen Therapeutics Completes Merger With Vaxart 14
Vaxart Raises USD18.4 Million in Private Placement of Notes 15
Vaxart Inc, Key Competitors 16
Vaxart Inc, Key Employees 17

List of Figures
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vaxart Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Vaxart Inc (VXRT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chronix Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Chronix Biomedical Inc (Chronix Biomedical) is a molecular diagnostic company that develops blood tests for monitoring minimal residual disease in cancer patients. The company offers tests such as second opinion tests and delta dot tests. Its second opinion tests include supplementary blood …
  • Foraco International SA (FAR):企業の財務・戦略的SWOT分析
    Summary Foraco International SA (Foraco) is a provider of drilling solutions for mining, energy, water and infrastructure projects. The company's drilling solutions include hydrogeological drilling, deep directional drilling, metallurgical sampling and large diameter drilling. It provides geological …
  • Coeur Mining, Inc:企業のM&A・事業提携・投資動向
    Coeur Mining, Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Coeur Mining, Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Dixons Carphone plc:企業の戦略・SWOT・財務情報
    Dixons Carphone plc - Strategy, SWOT and Corporate Finance Report Summary Dixons Carphone plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Precision Optics Corporation Inc (PEYE):企業の財務・戦略的SWOT分析
    Summary Precision Optics Corporation Inc (Precision Optics) is a medical device company that designs, develops, manufactures and distributes optics and optical systems for medical, biomedical, and industrial applications. The company provides custom optics solutions such as design and prototyping, f …
  • Banca Carige SpA (CRG):企業の財務・戦略的SWOT分析
    Banca Carige SpA (CRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Astron Corporation Ltd (ATR):企業の財務・戦略的SWOT分析
    Astron Corporation Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Top Frontier Investment Holdings Inc:企業の戦略・SWOT・財務分析
    Top Frontier Investment Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Top Frontier Investment Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Hey-Song Corporation:企業の戦略・SWOT・財務情報
    Hey-Song Corporation - Strategy, SWOT and Corporate Finance Report Summary Hey-Song Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Dah Chong Hong Holdings Ltd (1828):企業の財務・戦略的SWOT分析
    Dah Chong Hong Holdings Ltd (1828) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Original BioMedicals Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Original BioMedicals Co Ltd (OBM) is a biotechnology company that develops new drug delivering systems to deal with unmet clinical needs in the therapeutic areas of oncology, hematology and immunology. The company’s pipeline products include A01, A02 and P01. Its pipeline product OBM-A01 is …
  • Precision System Science Co Ltd (7707):企業の財務・戦略的SWOT分析
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company provide products such as automated nucleic acid isolation system, large sample volume nucleic acid extract …
  • Orell Fussli Holding AG:戦略・SWOT・企業財務分析
    Orell Fussli Holding AG - Strategy, SWOT and Corporate Finance Report Summary Orell Fussli Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Coca-Cola FEMSA SAB de CV:企業の戦略・SWOT・財務情報
    Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Carlsberg Brewery Malaysia Berhad:戦略・SWOT・企業財務分析
    Carlsberg Brewery Malaysia Berhad - Strategy, SWOT and Corporate Finance Report Summary Carlsberg Brewery Malaysia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Vedanta Ltd:企業の戦略・SWOT・財務情報
    Vedanta Ltd - Strategy, SWOT and Corporate Finance Report Summary Vedanta Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Bone Therapeutics SA (BOTHE):医療機器:M&Aディール及び事業提携情報
    Summary Bone Therapeutics SA (Bone Therapeutics) is a cell therapy company that develops autologous and allogeneic cell therapy products. The company offers pipeline products such as PREOB, an autologous osteoblastic cell therapy product used for the treatment of osteonecrosis and non-union fracture …
  • Sasol Ltd (SOL):石油・ガス:M&Aディール及び事業提携情報
    Summary Sasol Ltd (Sasol) is an integrated energy and chemicals company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and …
  • Abionic SA-医療機器分野:企業M&A・提携分析
    Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company offers products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE application for android, iPhone & iPad, and accessories. Its abioSCOPE in vitro tests are design …
  • Polenergia SA (PEP):電力:M&Aディール及び事業提携情報
    Summary Polenergia SA (Polenergia) formerly Polish Energy Partners SA develops, implements and operates projects related to production of electricity and fuels. It offers services such as project implementation and supervision of construction, management of power facilities, production and sales of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆